{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:56:43Z","timestamp":1771855003961,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1K23-AI134307"],"award-info":[{"award-number":["1K23-AI134307"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI068634"],"award-info":[{"award-number":["UM1-AI068634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI106701"],"award-info":[{"award-number":["UM1-AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI068636"],"award-info":[{"award-number":["UM1-AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug\u2013drug interactions with concomitantly used ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4\u2009weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine\/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL\/F) was estimated and the geometric mean ratio (GMR) of CL\/F prior to and during rifapentine\/isoniazid was calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13\u201366) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266\u20139302) ng\/mL; week 2, 5537 (3552\u20138462) ng\/mL; and week 4, 5388 (3516\u20138243) ng\/mL. Sixty out of 78 participants (77%) had nevirapine concentrations \u22653000\u2009ng\/mL at both week 2 and 4. Median (IQR) nevirapine CL\/F values were: week 0 pre-rifapentine\/isoniazid, 2.03 (1.58\u20132.58) L\/h; and during rifapentine\/isoniazid, 2.62 (1.81\u20133.42) L\/h. The GMR (90% CI) for nevirapine CL\/F was 1.30 (1.26\u20131.33).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The CL\/F of nevirapine significantly increased with concomitant rifapentine\/isoniazid. The decrease in nevirapine trough concentrations during rifapentine\/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug\u2013drug interaction suggests daily rifapentine\/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa470","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:20:27Z","timestamp":1603858827000},"page":"718-721","source":"Crossref","is-referenced-by-count":14,"title":["Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention"],"prefix":"10.1093","volume":"76","author":[{"given":"A T","family":"Podany","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Leon-Cruz","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Hakim","sequence":"additional","affiliation":[{"name":"Parirenyatwa CRS, Harare, Zimbabwe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Supparatpinyo","sequence":"additional","affiliation":[{"name":"Chiang Mai University HIV Treatment CRS, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Omoz-Oarhe","sequence":"additional","affiliation":[{"name":"Molepolole Clinical Research Site, Molepolole, Botswana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Langat","sequence":"additional","affiliation":[{"name":"Kenya Medical Research Institute\/Walter Reed Project Clinical Research Center CRS, Kericho, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Mwelase","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand Helen Joseph CRS, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Kanyama","sequence":"additional","affiliation":[{"name":"Malawi CRS, Lilongwe, Malawi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gupta","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C A","family":"Benson","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Swindells","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C V","family":"Fletcher","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the AIDS Clinical Trials Group A5279 Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Blanchard-Horan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Walawander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ebiasah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc Antoine","family":"JeanJuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Nicotera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shugarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Shali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimi","family":"Tutko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Demers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Maroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge L","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Lama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Matoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"do Amaral Calvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald Kibet","family":"Tonui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taolo","family":"Modise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Kasaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deelip","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Burman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2021021208575245800_dkaa470-B1","volume-title":"Methods Used by WHO to Estimate the Global Burden of TB Disease","author":"Glaziou","year":"2019"},{"key":"2021021208575245800_dkaa470-B2","volume-title":"Rapid Communication on Forthcoming Changes to the Programmatic Management of Tuberculosis Preventive Treatment","year":"2020"},{"key":"2021021208575245800_dkaa470-B3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2021021208575245800_dkaa470-B4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/00003088-200342060-00009","article-title":"Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population","volume":"42","author":"de Vries-Sluijs","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021021208575245800_dkaa470-B5","volume-title":"ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D\u2019Argenio","year":"2009"},{"key":"2021021208575245800_dkaa470-B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.43.1.121","article-title":"Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients","volume":"43","author":"Zhou","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575245800_dkaa470-B7","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575245800_dkaa470-B8","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1038\/s41598-020-69228-z","article-title":"Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics","volume":"10","author":"Dyavar","year":"2020","journal-title":"Sci Rep"},{"key":"2021021208575245800_dkaa470-B9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2021021208575245800_dkaa470-B10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208575245800_dkaa470-B11","article-title":"Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine","author":"Haas","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"2021021208575245800_dkaa470-B12","first-page":"895","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"2021021208575245800_dkaa470-B13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jac\/dkw388","article-title":"Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children","volume":"72","author":"Bienczak","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021021208575245800_dkaa470-B14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021021208575245800_dkaa470-B15","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/718\/36241188\/dkaa470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/718\/36241188\/dkaa470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:18:09Z","timestamp":1613175489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/718\/6006420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa470","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,30]]}}}